Cencora
COR
$318.04
+1.06%
Cencora, Inc. is a leading pharmaceutical wholesaler and healthcare solutions provider, distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and healthcare providers across the U.S. and Europe. As one of the 'Big Three' domestic wholesalers alongside McKesson and Cardinal Health, Cencora commands over 90% combined market share in the U.S. pharmaceutical distribution industry, distinguishing itself through its scale, global specialty logistics (World Courier), and animal health distribution (MWI Animal Health). The current investor narrative centers on the company's strategic expansion into higher-margin commercialization services and international markets, particularly following the 2021 acquisition of Alliance Healthcare, while navigating the challenges of a low-margin distribution model and recent earnings volatility. Recent attention has been drawn to the stock's sharp price swings, including a significant drop in May 2026, and the market's focus on margin recovery and operational efficiency in a competitive landscape.…
COR
Cencora
$318.04
Investment Opinion: Should I buy COR Today?
Based on the analysis, Cencora is rated a Hold. The stock offers a forward PE of 16.07x, which is attractive relative to its earnings potential, and the analyst consensus is Buy with an average target of $369.31, implying 16.1% upside. However, the high debt levels and volatile revenue growth introduce significant risks that temper enthusiasm. The company's dominant market position and low beta provide stability, but the elevated trailing PE and PEG ratio suggest that the stock is not a bargain at current levels.
Sign up to view all
COR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Cencora's valuation is reasonable on a forward basis, but the high leverage and decelerating growth introduce uncertainty. The stock's low beta provides some downside protection, but the negative relative strength over 6 months suggests weak momentum. If the company can deliver on earnings expectations and reduce debt, the stock could re-rate higher; otherwise, it may remain range-bound. Key factors to watch are quarterly earnings, margin trends, and interest rate movements.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $369.31 and implied upside of +16.1% versus the current price.
Average Target
$369.31
0 analysts
Implied Upside
+16.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$330 - $430
Analyst target range
The target price range spans from a low of $330.00 to a high of $430.00, representing a wide spread of $100, which indicates significant divergence in analyst expectations. The high target of $430 implies a 35.2% upside from the current price, likely assuming a successful margin expansion and multiple re-rating, while the low target of $330 suggests a more conservative scenario with limited upside (3.8%). The wide range reflects uncertainty around the pace of earnings normalization and the impact of competitive pressures. Recent institutional ratings show no downgrades, with firms like B of A Securities maintaining Neutral and others like Barclays and JP Morgan reiterating Overweight, indicating a stable but not overly aggressive sentiment. The absence of recent rating changes suggests analysts are waiting for more clarity on the company's margin trajectory before adjusting targets.
Bulls vs Bears: COR Investment Factors
Cencora presents a mixed picture: its dominant market position and attractive forward valuation are countered by high leverage and a rich trailing multiple. The bull case rests on earnings normalization driving the forward PE down to 16x, while the bear case highlights the elevated PEG and debt levels. Currently, the evidence slightly favors the bulls, as the forward PE suggests the market is pricing in a recovery that seems achievable given the company's stable revenue base. The key tension is whether the earnings recovery will be swift enough to justify the current price, or if margin pressures and competition will delay it, leading to further downside. Investors should monitor quarterly earnings for signs of margin expansion and debt reduction to resolve this debate.
Bullish
- Forward PE of 16x is attractive: The forward PE of 16.07x is significantly lower than the trailing PE of 38.97x, implying the market expects a substantial earnings recovery. This forward multiple is reasonable for a company with stable revenue and a dominant market position, offering potential upside if earnings normalize as expected.
- Dominant market position with 90%+ share: Cencora, along with McKesson and Cardinal Health, controls over 90% of the U.S. pharmaceutical distribution market. This oligopolistic structure provides pricing power and barriers to entry, supporting stable revenue streams and long-term competitive advantage.
- Analyst consensus is Buy with 16% upside: The average analyst target price is $369.31, implying a 16.1% upside from the current price of $318.04. With 13 analysts covering and a mean recommendation of 1.67 (Buy), the Street sees value, and the high target of $430 suggests potential for 35% upside if margin expansion materializes.
- Revenue growth remains positive at 3.85% YoY: In Q2 FY2026, revenue grew 3.85% year-over-year to $78.36 billion, driven by pharmaceutical distribution and the Alliance Healthcare acquisition. While growth has decelerated from 5.45% in Q1, the company continues to expand its top line, providing a foundation for earnings recovery.
Bearish
- Trailing PE of 39x is expensive: The trailing PE of 38.97x is elevated, reflecting depressed earnings due to one-time charges in recent quarters. If earnings do not recover as expected, the stock could face de-rating, as the current multiple is well above historical norms for a low-margin distributor.
- PEG ratio of 7.05x signals overvaluation: The PEG ratio of 7.05x indicates that the stock is expensive relative to its expected earnings growth. Even with a forward PE of 16x, the implied growth rate is not sufficient to justify the current valuation, suggesting limited upside unless growth accelerates significantly.
- High debt-to-equity of 7.13x increases financial risk: Cencora's debt-to-equity ratio of 7.13x is extremely high, reflecting significant leverage from the Alliance Healthcare acquisition. This leverage amplifies interest costs and reduces financial flexibility, making the company vulnerable to rising interest rates or cash flow disruptions.
- Revenue growth decelerating and volatile: Revenue growth slowed from 5.45% in Q1 FY2026 to 3.85% in Q2, and Q4 FY2025 saw a decline of 5.92% YoY. This volatility suggests that growth is not stable, and the low-margin nature of distribution means top-line growth has limited impact on earnings.
COR Technical Analysis
Cencora's stock has exhibited a volatile, range-bound pattern over the past year, with a 1-year price change of +4.88% and a 6-month change of -11.92%, indicating a lack of sustained directional trend. The current price of $318.04 sits at approximately 84% of the 52-week range (low $244.82, high $377.54), suggesting the stock is in the upper-middle portion of its range, reflecting a recovery from recent lows but still below its highs. This positioning implies a cautious optimism, as the stock has rebounded from its May 2026 trough but has not yet reclaimed its February 2026 peak, leaving room for either a breakout or a rollover.
Beta
0.57
0.57x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
+4.9%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | +3.6% |
| 3m | +15.7% | +2.7% |
| 6m | -11.9% | +11.4% |
| 1y | +4.9% | +18.7% |
| ytd | -6.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Cencora's revenue trajectory shows moderate growth, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting revenue of $78.36 billion, up 3.85% year-over-year from $75.45 billion in the prior-year quarter. However, growth has been uneven: Q1 FY2026 revenue was $85.93 billion, a 5.45% increase from $81.49 billion in Q1 FY2025, but Q4 FY2025 saw a decline of 5.92% year-over-year, indicating volatility. The multi-quarter trend shows a deceleration from the 5.45% growth in Q1 to 3.85% in Q2, suggesting a slowdown, though the company's scale and diversified segments (Animal Health and Other Segments) provide some stability. The revenue growth is driven by pharmaceutical distribution volume and the contribution from Alliance Healthcare, but the low-margin nature of distribution keeps the growth's bottom-line impact modest.
Quarterly Revenue
$78.4B
2026-03
Revenue YoY Growth
+3.9%
YoY Comparison
Gross Margin
4.2%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Given Cencora's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE stands at 38.97x, while the forward PE is 16.07x, a significant gap that implies the market expects a substantial earnings increase in the coming year, likely due to the recovery from the one-time charges that depressed trailing earnings. This forward multiple suggests a more reasonable valuation relative to near-term earnings power, but the trailing PE is elevated, reflecting the earnings trough. The PEG ratio of 7.05x indicates that the stock is not cheap on a growth-adjusted basis, as the expected earnings growth is not sufficient to justify the current multiple.
PE
39.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for Cencora. The company's debt-to-equity ratio of 7.13x is extremely high, indicating a heavy reliance on borrowed funds, which increases interest expenses and reduces net income. In Q2 FY2026, interest expense was $154.3 million, and with a net margin of only 0.48%, any rise in interest rates could severely impact profitability. Additionally, the company's gross margin is razor-thin at 3.16%, leaving little room for error in cost management. Revenue growth is also volatile, with Q4 FY2025 showing a 5.92% decline, and the recent deceleration from 5.45% to 3.85% suggests that top-line momentum is fading, which could pressure earnings if not offset by cost cuts.
FAQ
The key risks for Cencora include: 1) Financial risk from high leverage, with a debt-to-equity ratio of 7.13x, which could strain cash flow if interest rates rise; 2) Operational risk from thin margins (gross margin of 3.16%), leaving little room for error; 3) Competitive risk from McKesson and Cardinal Health, which could lead to price wars; 4) Macro risk from regulatory changes in drug pricing. The most severe risk is a prolonged earnings recession, which could push the stock down to its 52-week low of $244.82, a 23% downside.
The 12-month forecast for Cencora is cautiously optimistic. The base case, with a 50% probability, sees the stock trading in the $330-$370 range, aligning with the analyst average target of $369.31. The bull case, with a 30% probability, could push the stock to $430 if earnings recovery is strong, while the bear case, with a 20% probability, could see it fall to $245 if margins deteriorate. The most likely scenario is moderate growth, driven by stable revenue and margin stabilization, but the high debt remains a key risk.
Cencora is fairly valued on a forward basis but overvalued on a trailing basis. The forward PE of 16.07x is reasonable for a company with stable revenue, while the trailing PE of 38.97x is elevated due to depressed earnings. The PEG ratio of 7.05x suggests that the stock is expensive relative to its growth prospects, indicating that the market expects a significant earnings rebound. Compared to peers, the forward PE is in line with the sector, but the high debt levels warrant a discount. Overall, the stock is not a bargain, but it is not excessively overvalued if earnings meet expectations.
Cencora is a moderate buy for investors seeking a defensive healthcare stock with a reasonable forward valuation. The stock trades at a forward PE of 16.07x, which is attractive given the expected earnings recovery, and analysts see 16% upside to the average target of $369.31. However, the high debt-to-equity ratio of 7.13x and thin margins introduce risk, so it is not a high-conviction buy. It is best suited for investors with a medium risk tolerance who are willing to hold for at least 12 months to see the earnings recovery play out.
Cencora is more suitable for long-term investment due to its defensive characteristics and low beta of 0.57. The stock offers a modest dividend yield of 0.72% and has the potential for capital appreciation as earnings recover. Short-term trading is possible, but the stock's volatility (as seen in the May 2026 drop) makes it risky for traders. A minimum holding period of 12-18 months is recommended to allow the earnings recovery to materialize and for the stock to reach its fair value. Long-term investors can benefit from the company's dominant market position and stable cash flows.